Hemorrhagic complications with prasugrel therapy for vascular neurointerventional procedures

Journal of NeuroInterventional Surgery

Volumn 5, Issue 4, 2013, Pages 344-345

  Leslie Mazwi, Thabele M ^a   Chandra, Ronil V ^a   Yoo, Albert J ^a   Rabinov, James D ^a   Hirsch, Joshua A ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; CLOPIDOGREL; EPTIFIBATIDE; PRASUGREL; TICAGRELOR;

BLEEDING; BRAIN CIRCULATION; DOSAGE SCHEDULE COMPARISON; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; HUMAN; ISCHEMIA; MEDICAL PROCEDURES; NERVOUS SYSTEM; NEUROINTERVENTIONAL PROCEDURE; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; NOTE; POINT OF CARE TESTING; PRIORITY JOURNAL; RETROPERITONEAL HEMATOMA; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION INHIBITION; THROMBOSIS; UNSTABLE ANGINA PECTORIS;

ANEURYSM; ANGIOGRAPHY; ANGIOPLASTY; ARTERIOVENOUS MALFORMATION; ARTERY; ATHEROSCLEROSIS; BRAIN; FISTULA; SPINE; STENOSIS; STENT; STROKE; SUBARACHNOID; THROMBECTOMY;

CEREBRAL HEMORRHAGE; EMBOLIZATION, THERAPEUTIC; ENDOVASCULAR PROCEDURES; FEMALE; HUMANS; MALE; NEUROPROTECTIVE AGENTS; PIPERAZINES; PURINERGIC P2X RECEPTOR ANTAGONISTS; PURINERGIC P2Y RECEPTOR ANTAGONISTS; THIOPHENES;

EID: 84879382221     PISSN: 17598478     EISSN: 17598486     Source Type: Journal    
DOI: 10.1136/neurintsurg-2012-010406     Document Type: Note

References (11)

1. Reynolds M, Kadkhodayan Y, Cross DWC III, et al. Hemorrhagic Complications after Prasugrel (Effient®) Therapy for Vascular Neurointerventional Procedures. J NeuroIntervent Surg. Published Online First: 3 May 2012. doi:10.1136/neurintsurg-2012-010334
2. Gemmete JJ, Chaudhary N, Pandey AS, et al. Prasugrel is Effective and Safe for Neuro- Interventional Procedures. J NeuroIntervent Surg 2012. doi:10.1136/neurintsurg-2012-010302
3. Simon T, Verstuyft C, Mary-Krause M, et al. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med 2009;360:363-375.
4. Patti G, Nusca A, Mangiacapra F, et al. Point-of-care measurement of clopidogrel responsiveness predicts clinical outcome in patients undergoing percutaneous coronary intervention results of the ARMYDA-PRO (antiplatelet therapy for reduction of myocardial damage during angioplasty-platelet reactivity predicts outcome) study. J Am Coll Cardiol 2008;52:1128-133.
5. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, et al. Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives. J Am Coll Cardiol 2007;49:1505-1516.
6. Combescure C, Fontana P, Mallouk N, et al. Clinical implications of clopidogrel non-response in cardiovascular patients: a systematic review and meta-analysis. J Thromb Haemost 2010;8:923-933.
7. Leslie-Mazwi TM, Chandra RV, Oh DC, et al. Novel use of prasugrel for intracranial stent thrombosis. J Neurointerv Surg. Published Online First: 18 February 2011.
8. Wright RS, Anderson JL, Adams CD, et al. 2011 ACCF/AHA focused update of the guidelines for the management of patients with unstable angina/non- ST-elevation myocardial infarction (updating the 2007 guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines developed in collaboration with the American College of Emergency Physicians, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol 2011;57:1920-1959.
9. Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009;361:1045-1057.
10. Geeganage C, Wilcox R, Bath PM. Triple antiplatelet therapy for preventing vascular events: a systematic review and meta-analysis. BMC Med 2010;8:36.
11. Meyers PM, Blackham KA, Abruzzo TA, et al. Society of neurointerventional surgery standards of practice: general considerations. J Neurointerv Surg 2012;4:11-15.